Spark Biomedical Taps AcuityMD to “Turbo-Charge” Efforts to Build New Market of Non-Invasive Therapeutics for Opioid Use Disorder

Spark Biomedical, a leading developer of wearable neurostimulation solutions, has partnered with AcuityMD, a commercial platform provider for medical technology companies, to accelerate Spark Biomedical’s expansion of a new and growing market for treatment of withdrawal associated with opioid use disorder. Spark Biomedical’s FDA-approved Sparrow Therapy System is a drug-free tool that includes a patient controller and earpiece that send mild electrical impulses to the brain to help alleviate opiate withdrawal symptoms.

AcuityMD’s data-driven targeting platform supports Spark Biomedical’s ambitious goals of providing a safe pathway to life-restoring sobriety to the millions of people suffering from opioid addiction.

Overdose deaths involving prescription opioids increased more than 20% in 2020, widely attributed to pandemic-related mental health issues. In addition, growth in drug use has caused overdose deaths from synthetic opioids such as fentanyl, which increased by more than 50% from 2019 to 2020. Spark Biomedical novel therapeutic aids detoxification with 84% of participants experiencing mild to no withdrawal symptoms within 60 minutes of therapy. And, after two days of treatment, 100% of patients sustained a clinically meaningful reduction in opioid withdrawal.

“In the treatment of substance abuse disorders, we need to address the entire continuum of care,” said Dan Wagner, Chief Commercial Officer for Spark Biomedical. “It starts with education and de-stigmatization, and continues to detoxification, therapy, and a lifetime of support. It is difficult to identify optimal channels for product adoption, so we are taking every effort to understand the treating physicians, therapists, rehab facilities, caregivers, and patients. AcuityMD’s targeting platform is the linchpin to this process, helping expand access and bring our device to more patients faster.”

The Sparrow Therapy System is already in use in more than two dozen rehabilitation facilities nationwide, but the company aspires to increase market penetration of its next-generation system with AcuityMD. Thousands of sales and marketing professionals from pre-commercial to enterprise medical device companies use AcuityMD’s commercial platform to improve targeting and planning, increase productivity, and accelerate patient access to innovative medical technology. AcuityMD’s most active users typically achieve a 25% increase in sales.

“Spark Biomedical is working tirelessly to help end the opioid epidemic in America, so we consider it very high praise to be chosen as their partner,” said Michael Monovoukas, CEO and co-founder of AcuityMD, which recently raised $31 million in Series A funding. “Since 2021, medical device companies have identified more than 40,000 new opportunities using our software, each one an opportunity to bring life-changing medical technology to more patients – the ultimate goal for both us and Spark Biomedical.”

“AcuityMD’s data-driven, intuitive platform is helping us turbo-charge our go-to-market efforts, so we can strategically get the right device in front of the right people at the right time,” concluded Spark Biomedical’s Dan Wagner. “And, given this country’s overdose rates, there’s no time to waste.”

Learn more about how Spark Biomedical is changing how substance abuse is treated with AcuityMD at the AdvaMed MedTech Conference 2022 (October 24-26, 2022) at the Boston Convention & Exhibition Center.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“It’s exciting to be one of the first two hospitals in Europe to use Stryker’s Mixed Reality Guidance System,” said Professor Berhouet. “I am also pleased to be leading a pilot study to investigate the safety and effectiveness of this new technology, alongside three other centres in France.”
The KnowU incorporates the sensor that the Company plans to submit to the FDA for clearance. This proprietary sensor has been tested and proven stable and accurate in the lab setting. It was included in the Company’s prototype to validate stability outside of the lab, and is now miniaturized and wearable.
The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy